Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis
NCT ID: NCT01996423
Last Updated: 2015-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
101 participants
INTERVENTIONAL
2014-04-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D in Egyptian Children With Atopic Dermatitis
NCT04468711
Vitamin D Treatment Effect for Atopic Dermatitis in Children
NCT05523986
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis
NCT01234909
Effect of Oral Vitamin D Supplement on Atopic Dermatitis; A Clinical Trial With Staphylococcus Aureus Colonization Determination
NCT02058186
Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3
NCT00789880
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D3 supplementation
Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
Vitamin D3
Placebo
Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D3
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 2 - 17 years
* SCORAD 10 - 103
Exclusion Criteria
* History of underlying illness causing immunosuppression within the past 2 years
* Immunosuppressors taken within the past month
* Parathyroid disease
* Sarcoidosis
* Acute or chronic renal disease
* Hyper or hypocalcemia
* Thyroid disease
* Osteomalacia or Paget's disease of bone
* Malabsorption
* Use of VD supplements (\> 400 IU daily) or fish oil supplements in the past month
* Treatment for known VD deficiency in the last 6 months
* Treatment with moderate or high potency topical corticosteroids, oral or topical antibiotics, oral antivirals, immune enhancers, or topical calcineurin inhibitors in the past 7 days
* Phototherapy in the past month
* Autoimmune disease or immunodeficiency
* Planned trip to sunny climate during the 6-week study.
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pontificia Universidad Catolica de Chile
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arturo Borzutzky, M.D.
Role: PRINCIPAL_INVESTIGATOR
School of Medicine, Pontificia Universidad Católica de Chile
Carlos A Camargo Jr., M.D., DrPH
Role: STUDY_DIRECTOR
Massachusetts General Hospital, Harvard University, Boston, USA
Cristian Vera, M.D.
Role: STUDY_DIRECTOR
School of Medicine, Pontificia Universidad Católica de Chile
Lorena Cifuentes, M.D.
Role: STUDY_DIRECTOR
School of Medicine, Pontificia Universidad Católica de Chile
Sergio Silva, M.D.
Role: STUDY_DIRECTOR
School of Medicine, Pontificia Universidad Católica de Chile
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Medicine, Pontificia Universidad Católica de Chile
Santiago, , Chile
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Borzutzky A, Iturriaga C, Perez-Mateluna G, Cristi F, Cifuentes L, Silva-Valenzuela S, Vera-Kellet C, Cabalin C, Hoyos-Bachiloglu R, Navarrete-Dechent C, Cossio ML, Le Roy C, Camargo CA Jr. Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2024 Sep;38(9):1760-1768. doi: 10.1111/jdv.19959. Epub 2024 Mar 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1130615
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
12-185
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.